Does NVST Stock Still Deserve a Place in Your Portfolio?
Envista executes on growth priorities with new products, acquisitions and global expansion, but macro, tariff and currency headwinds remain in focus.
Zacks Investment Research7/9/2026Neutral
NVST
Envista Holdings CorpNYSEHEALTHCAREMEDICAL INSTRUMENTS & SUPPLIES
Key Statistics
Market Cap
$4.41B
P/E Ratio
66.17
EPS
$0.41
Beta
0.86
52W High
$30.42
52W Low
$18.77
50-Day MA
$24.91
200-Day MA
$23.77
Dividend Yield
—
Profit Margin
2.41%
Forward P/E
20.33
PEG Ratio
—
About Envista Holdings Corp
Envista Holdings Corporation, develops, manufactures and markets dental products in the United States and internationally. The company is headquartered in Brea, California.
Fundamentals
| Revenue (TTM) | $2.81B |
| Gross Profit (TTM) | $1.55B |
| EBITDA | $383.10M |
| Operating Margin | 9.87% |
| Return on Equity | 2.21% |
| Return on Assets | 3.01% |
| Revenue/Share (TTM) | $16.93 |
| Book Value | $18.90 |
| Price-to-Book | 1.46 |
| Price-to-Sales (TTM) | 1.57 |
| EV/Revenue | 1.782 |
| EV/EBITDA | 12.90 |
| Quarterly Earnings Growth (YoY) | 130.00% |
| Quarterly Revenue Growth (YoY) | 14.40% |
| Shares Outstanding | $162.73M |
| Float | $162.03M |
| % Insiders | 0.48% |
| % Institutions | 113.32% |
Historical Volatility
HV 10-Day
42.29%
HV 20-Day
38.52%
HV 30-Day
34.10%
HV 60-Day
37.32%
HV Rank
46.8%
Volatility is currently expanding
Analyst Ratings
Consensus ($29.62 target)
1
Strong Buy6
Buy8
HoldLatest News
Envista Schedules Second Quarter 2026 Earnings Call
BREA, Calif., July 7, 2026 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") will report financial results for its second quarter 2026 on Wednesday, August 5, 2026.
PRNewsWire7/7/2026Neutral
NVST Stock Rallies 37.1% in a Year: What's Behind the Drive?
Envista rises 37.1% in a year as new dental product launches, margin gains, acquisitions and a strong balance sheet fuel growth.
Zacks Investment Research6/19/2026Positive
Here's Why You Should Retain NVST Stock in Your Portfolio for Now
Envista Holdings Corporation's NVST ongoing international expansion is strengthening its presence across a broader range of markets, creating significant opportunities for long-term growth. Supported by the company's strategic priorities and growth-focused initiatives, it is well positioned to capitalize on emerging opportunities and deliver solid operational and financial performance in the upcoming quarters.
Zacks Investment Research6/8/2026Positive
Why Is Envista (NVST) Down 5.9% Since Last Earnings Report?
Envista (NVST) reported earnings 30 days ago. What's next for the stock?
Zacks Investment Research6/5/2026Negative
Is NVST Attractive at 15.1x Forward Earnings?
Envista trades at 15.1x forward earnings; Q1 2026 profit surged, and a $24 target hinges on sustaining margins and sales gains.
Zacks Investment Research6/4/2026Positive
NVST Stock Explained for 2026 Growth Drivers and Risks
Envista targets margin gains via its Business System while boosting R&D and buybacks, with a $24 6-12 month target vs $22.94.
Zacks Investment Research6/3/2026Positive
Here's Why Envista (NVST) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Investment Research6/2/2026Positive
Why Envista (NVST) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks Investment Research5/15/2026Positive
Americans Are Cutting Spending on Everything Except Healthcare. These 2 Medical Device Stocks Under $30 Are Built to Win
With consumer sentiment sitting at 53.3 in March 2026, deep in pessimistic territory, retail investors are hunting for defensive names that can grow even as households tighten budgets.
24/7 Wall Street5/13/2026Neutral
More HEALTHCARE Stocks
Data last updated: 7/9/2026